This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

trusted source

proofread

New research discovery could shorten ICU stays for children with diabetic ketoacidosis

vaccine vials
Credit: Pixabay/CC0 Public Domain

When a child with diabetic ketoacidosis (DKA) requires intensive care, clinicians often monitor blood ketone levels to determine whether treatment has successfully reversed the abnormal ketone production. Yet, the utility of blood ketone levels to diagnose DKA or determine whether a child's DKA has resolved have not been rigorously studied.

But now, research by Elise Tremblay, MD, and others in Boston Children's divisions of Endocrinology and Medical Critical Care and Department of Cardiology shows that a particular value of plasma beta-hydroxybutyrate (BOHB) can signal that DKA has clinically resolved and intensive treatment can stop.

Widespread adoption of this defined endpoint could remove some of the uncertainty from monitoring DKA. It could potentially end intensive care at the right time—instead of having it extend unnecessarily—and free up ICU resources, Tremblay says.

Improving accuracy in ketone measurement

When a with type 1 diabetes doesn't have enough insulin, their body produces a large amount of ketones—a breakdown product of fats that the brain can use for metabolism. Ketones are acidic and if the level of ketones gets too high, a child can develop life-threatening DKA.

For years, the only way to measure ketones in was through urine. Yet, that method didn't reflect real-time levels of ketone, and it specifically measured acetoacetate, a ketone whose concentration in the is significantly less than that of BOHB, the most prominent ketone present in DKA.

But recently, measurement of BOHB has become feasible thanks to . It can be measured in a in a clinical chemistry laboratory, or through a fingerstick blood test with a handheld meter. In 2021, Tremblay and her colleagues found that BOHB can accurately predict DKA in children and adolescents who are in emergency room care. The finding set the stage for the latest round of research: arriving at an endpoint for DKA treatment.

A new DKA threshold could shorten hospital stays

For the current study, published in Pediatric Diabetes, Tremblay and her colleagues analyzed data from 403 hospitalized children who were treated for DKA with intravenous insulin and whose levels of BOHB were measured during that time.

Based on this information, the team determined a BOHB value of intensive care of DKA can end. And with the use of handheld blood ketone meters to measure BOHB, which correlate well with laboratory measurements up to approximately 5 mmol/L, it could also provide some hospitals with a simpler, more accessible way to define resolution of DKA.

"In many countries, hospitals and health care facilities do not have access to well-resourced clinical chemistry laboratories," Tremblay says. "Being able to determine if a child has DKA through a simple point-of-care blood test could aid physicians working in facilities with limited resources to efficiently diagnose and treat DKA."

More information: Elise Schlissel Tremblay et al, Utility of plasma beta‐hydroxybutyrate to define resolution of diabetic ketoacidosis, Pediatric Diabetes (2022). DOI: 10.1111/pedi.13437

Citation: New research discovery could shorten ICU stays for children with diabetic ketoacidosis (2023, February 17) retrieved 19 July 2024 from https://medicalxpress.com/news/2023-02-discovery-shorten-icu-stays-children.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Ketone monitoring infrequent in patients with type 1 diabetes

34 shares

Feedback to editors